ARCT Live signals | Maximize Profits with Getagraph.com

BUY 94454 min ago

@ $38.32

Issued: 14 Feb 2024 @ 15:08

Return: -32.20%

Previous signal: Feb 13 - 15:48

Previous signal: Sell

Return: -0.52 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States...

Stats
Today's Volume	622 424
Average Volume	483 438
Market Cap	699.26M
EPS	$0 ( 2024-03-07 )
Next earnings date	( $-0.790 ) 2024-05-14
Last Dividend	$0.0596 ( 2013-01-08 )
Next Dividend	$0 ( N/A )
P/E	-23.20
ATR14	$0.0510 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Chivukula Pad	Sell	17 435	Common Stock
2024-03-19	Chivukula Pad	Sell	8 565	Common Stock
2023-12-15	Sassine Andy	Buy	75 000	Employee Stock Option (right to buy)
2023-12-15	Chivukula Pad	Buy	125 000	Employee Stock Option (right to buy)
2023-12-15	Kurata Lance	Buy	75 000	Employee Stock Option (right to buy)

INSIDER POWER
78.30
Last 97 transactions
Buy: 2 555 134 \| Sell: 1 046 972

Volume Correlation

Long: 0.27 (neutral)

Short: 0.16 (neutral)

Signal:(54.964) Neutral

Arcturus Therapeutics Correlation

10 Most Positive Correlations
AVEO	0.955
ITMR	0.949
RBNC	0.939
HEAR	0.932
SUMR	0.929
FCBP	0.92
DVCR	0.92
RMRM	0.918
AMYT	0.917
EA	0.917

10 Most Negative Correlations
SBNY	-0.929
IMV	-0.925
DPRO	-0.92
NDRA	-0.913
MNDO	-0.91
CLDX	-0.909
SSPK	-0.909
WABC	-0.908
DFFN	-0.907
TCBC	-0.907

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Arcturus Therapeutics Correlation - Currency/Commodity

0.67
( moderate )

0.39
( neutral )

0.00
( neutral )

0.31
( neutral )

0.14
( neutral )

0.23
( neutral )

Arcturus Therapeutics Financials

Annual	2023
Revenue:	$157.75M
Gross Profit:	$154.79M (98.13 %)
EPS:	$-1.120

Q4	2023
Revenue:	$28.21M
Gross Profit:	$27.40M (97.11 %)
EPS:	$-0.320

Q3	2023
Revenue:	$43.38M
Gross Profit:	$42.58M (98.16 %)
EPS:	$-0.610

Q2	2023
Revenue:	$9.57M
Gross Profit:	$-43.10M (-450.63 %)
EPS:	$-1.980

Financial Reports:

No articles found.

Arcturus Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Arcturus Therapeutics Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.571 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0200	2012-03-06
Last Dividend	$0.0596	2013-01-08
Next Dividend	$0	N/A
Payout Date	2013-01-15
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	$0.679	--
Avg. Dividend % Per Year	0.00%	--
Score	2.12	--
Div. Sustainability Score	1.571
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-18)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

2.12

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2012	$0	0.00%
2013	$0.119	0.23%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.165	1.500	-3.31	-4.96	[0 - 0.5]
returnOnAssetsTTM	-0.0619	1.200	-2.06	-2.48	[0 - 0.3]
returnOnEquityTTM	-0.0907	1.500	-2.12	-3.18	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.72	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.62	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	4.23	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0704	-1.500	8.83	-10.00	[0 - 0.6]
interestCoverageTTM	-92.63	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.677	2.00	-0.226	-0.451	[0 - 30]
freeCashFlowPerShareTTM	-0.784	2.00	-0.392	-0.784	[0 - 20]
debtEquityRatioTTM	0.108	-1.500	9.57	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.341	1.000	7.65	7.65	[0.2 - 0.8]
operatingProfitMarginTTM	-0.442	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.596	1.000	-4.42	-4.42	[0.2 - 2]
assetTurnoverTTM	0.375	0.800	-0.836	-0.668	[0.5 - 2]
Total Score				1.571

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-31.88	1.000	-3.32	0	[1 - 100]
returnOnEquityTTM	-0.0907	2.50	-1.362	-3.18	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.784	2.00	-0.261	-0.784	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.677	2.00	-0.226	-0.451	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.532	1.500	-6.88	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.112	1.000	-5.30	0	[0.1 - 0.5]
Total Score				-2.30

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.